$STIM
Neuronetics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020036161 Filed on August 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $9.741M $16.57M $12.73M
YoY Change -41.22% 25.05% 25.37%
Cost Of Revenue $2.323M $4.171M $2.807M
YoY Change -44.31% 28.54% 14.25%
Gross Profit $7.418M $12.40M $9.921M
YoY Change -40.18% 23.92% 28.93%
Gross Profit Margin 76.15% 74.83% 77.95%
Selling, General & Admin $12.16M $15.78M $14.19M
YoY Change -22.95% 22.23% 32.07%
% of Gross Profit 163.94% 127.28% 143.04%
Research & Development $2.116M $3.224M $2.786M
YoY Change -34.37% 38.37% 79.16%
% of Gross Profit 28.53% 26.0% 28.08%
Depreciation & Amortization $230.0K $260.0K $204.0K
YoY Change -11.54% -13.33% 46.76%
% of Gross Profit 3.1% 2.1% 2.06%
Operating Expenses $14.28M $19.01M $16.98M
YoY Change -24.89% 24.7% 38.02%
Operating Profit -$6.859M -$6.607M -$7.056M
YoY Change 3.81% 26.18% 53.22%
Interest Expense $986.0K $931.0K $919.0K
YoY Change 5.91% 3.44% -0.22%
% of Operating Profit
Other Income/Expense, Net $80.00K $444.0K $446.0K
YoY Change -81.98% -132.65% 1437.93%
Pretax Income -$7.770M -$7.090M -$7.530M
YoY Change 9.59% -5.47% 36.91%
Income Tax
% Of Pretax Income
Net Earnings -$7.765M -$7.094M -$7.529M
YoY Change 9.46% -5.36% 36.97%
Net Earnings / Revenue -79.71% -42.81% -59.15%
Basic Earnings Per Share -$0.41
Diluted Earnings Per Share -$0.41 -$386.4K -$417.6K
COMMON SHARES
Basic Shares Outstanding 18.75M 18.31M
Diluted Shares Outstanding 18.75M

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.00M $89.60M $96.10M
YoY Change -39.73% 517.93% 371.08%
Cash & Equivalents $54.00M $89.64M $96.15M
Short-Term Investments
Other Short-Term Assets $1.900M $1.300M $1.700M
YoY Change 46.15% -69.77% -32.0%
Inventory $3.332M $2.552M $2.410M
Prepaid Expenses $851.0K $237.0K $59.00K
Receivables $6.636M $7.563M $5.666M
Other Receivables $1.300M $200.0K $100.0K
Total Short-Term Assets $67.21M $101.3M $106.0M
YoY Change -33.65% 289.59% 255.85%
LONG-TERM ASSETS
Property, Plant & Equipment $828.0K $1.105M $1.210M
YoY Change -25.07% -25.99% -13.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.922M $1.284M $1.390M
YoY Change 49.69% 50.88% 73.75%
Total Long-Term Assets $12.78M $8.129M $7.394M
YoY Change 57.24% 246.8% 236.09%
TOTAL ASSETS
Total Short-Term Assets $67.21M $101.3M $106.0M
Total Long-Term Assets $12.78M $8.129M $7.394M
Total Assets $79.99M $109.4M $113.4M
YoY Change -26.9% 286.05% 254.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.324M $3.659M $2.588M
YoY Change -36.49% 24.97% -13.73%
Accrued Expenses $5.661M $6.476M $6.291M
YoY Change -12.58% -16.23% 10.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $34.37M $3.750M
YoY Change 816.61% 50.0%
Total Short-Term Liabilities $45.35M $16.61M $11.86M
YoY Change 173.07% 11.87% 15.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $27.01M $30.57M
YoY Change -100.0% -1.78% 0.9%
Other Long-Term Liabilities $5.200M $6.000M $5.600M
YoY Change -13.33% 172.73% 143.48%
Total Long-Term Liabilities $5.200M $27.01M $30.57M
YoY Change -80.75% -1.78% -6.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $45.35M $16.61M $11.86M
Total Long-Term Liabilities $5.200M $27.01M $30.57M
Total Liabilities $50.55M $49.61M $48.02M
YoY Change 1.91% 6.73% 11.93%
SHAREHOLDERS EQUITY
Retained Earnings -$270.5M -$235.7M -$228.6M
YoY Change 14.78% 12.25%
Common Stock $299.9M $295.5M $294.0M
YoY Change 1.5% 6230.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.44M $59.82M $65.42M
YoY Change
Total Liabilities & Shareholders Equity $79.99M $109.4M $113.4M
YoY Change -26.9% 286.05% 254.49%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$7.765M -$7.094M -$7.529M
YoY Change 9.46% -5.36% 36.97%
Depreciation, Depletion And Amortization $230.0K $260.0K $204.0K
YoY Change -11.54% -13.33% 46.76%
Cash From Operating Activities -$9.480M -$6.850M -$9.570M
YoY Change 38.39% 34.31% 15.34%
INVESTING ACTIVITIES
Capital Expenditures -$210.0K -$130.0K -$270.0K
YoY Change 61.54% -38.1% -10.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$210.0K -$130.0K -$274.0K
YoY Change 61.54% -38.1% -7.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 470.0K 1.407M
YoY Change -91.49% -195.92% -807.04%
NET CHANGE
Cash From Operating Activities -9.480M -6.850M -9.570M
Cash From Investing Activities -210.0K -130.0K -274.0K
Cash From Financing Activities 40.00K 470.0K 1.407M
Net Change In Cash -9.650M -6.510M -8.437M
YoY Change 48.23% 12.24% -4.05%
FREE CASH FLOW
Cash From Operating Activities -$9.480M -$6.850M -$9.570M
Capital Expenditures -$210.0K -$130.0K -$270.0K
Free Cash Flow -$9.270M -$6.720M -$9.300M
YoY Change 37.95% 37.42% 16.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75708000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6569000
CY2020Q2 us-gaap Inventory Net
InventoryNet
3332000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
11250000
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
610
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6636000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27693000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2619000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18809000
us-gaap Operating Expenses
OperatingExpenses
35985000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7094000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
47852000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
76000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
36511000
us-gaap Profit Loss
ProfitLoss
-20378000
us-gaap Profit Loss
ProfitLoss
-14623000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
534000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
457000
us-gaap Share Based Compensation
ShareBasedCompensation
1842000
us-gaap Share Based Compensation
ShareBasedCompensation
1523000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
944000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
362000
stim Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
122000
stim Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
77000
stim Non Cash Gains Losses On Extinguishment Of Debt
NonCashGainsLossesOnExtinguishmentOfDebt
-622000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
66000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1216000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
557000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
82000
stim Increase Decrease In Net Investment In Sales Type Leases
IncreaseDecreaseInNetInvestmentInSalesTypeLeases
777000
stim Increase Decrease In Net Investment In Sales Type Leases
IncreaseDecreaseInNetInvestmentInSalesTypeLeases
640000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12613000
us-gaap Gross Profit
GrossProfit
16083000
us-gaap Gross Profit
GrossProfit
22322000
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11523000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18874000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
21115000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4010000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4261000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9298000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2116000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3224000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
14277000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6978000
CY2019Q4 us-gaap Liabilities
Liabilities
52316000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53997000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
188000
CY2020Q2 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
1305000
CY2019Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
880000
dei Local Phone Number
LocalPhoneNumber
640-4202
dei Security12b Title
Security12bTitle
Common Stock ($0.01 par value)
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
186000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
851000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
689000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1091000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3271000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3610000
CY2020Q2 us-gaap Liabilities
Liabilities
50554000
CY2019Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
1730000
CY2020Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
4340000
CY2019Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
3779000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1922000
CY2020Q2 us-gaap Assets
Assets
79994000
CY2019Q4 us-gaap Assets
Assets
100168000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2324000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4625000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5661000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9031000
CY2020Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2413000
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2228000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
577000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
559000
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
34373000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
45348000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19898000
CY2020Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1935000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2106000
CY2019Q4 us-gaap Inventory Net
InventoryNet
2775000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
67212000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
828000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1305000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1196000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3492000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
14000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-366000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16418000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
47852000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79994000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100168000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9741000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16572000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
299717000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
297753000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-270465000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250087000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
29440000
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18809000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21217000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18645000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18645000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29300000
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2323000
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4171000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5134000
CY2020Q2 us-gaap Gross Profit
GrossProfit
7418000
CY2019Q2 us-gaap Gross Profit
GrossProfit
12401000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8151000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8860000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5137000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6010000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
19008000
us-gaap Operating Expenses
OperatingExpenses
33309000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6859000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6607000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17226000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13663000
CY2020Q2 us-gaap Interest Expense
InterestExpense
986000
CY2019Q2 us-gaap Interest Expense
InterestExpense
931000
us-gaap Interest Expense
InterestExpense
2509000
us-gaap Interest Expense
InterestExpense
1850000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-924000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
80000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
444000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
281000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
890000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7765000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7094000
us-gaap Net Income Loss
NetIncomeLoss
-20378000
us-gaap Net Income Loss
NetIncomeLoss
-14623000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18747000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18351000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18714000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18189000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
71042000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1407000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
501000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7529000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
65421000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1022000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
59819000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
646000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7765000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
29440000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
470000
stim Increase Decrease In Leasehold Reimbursement
IncreaseDecreaseInLeaseholdReimbursement
-836000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104583000
us-gaap Interest Paid Net
InterestPaidNet
2227000
us-gaap Interest Paid Net
InterestPaidNet
1494000
stim Transfer Of Inventory To Property And Equipment
TransferOfInventoryToPropertyAndEquipment
37000
stim Increase Decrease In Prepaid Commission Expense
IncreaseDecreaseInPrepaidCommissionExpense
723000
stim Increase Decrease In Prepaid Commission Expense
IncreaseDecreaseInPrepaidCommissionExpense
1579000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-356000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-941000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2408000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-228000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1044000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23131000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
484000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
398000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-484000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-398000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
41360000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
38860000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
721000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
124000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1877000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1903000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1877000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-21711000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14939000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75708000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53997000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89644000
us-gaap Nature Of Operations
NatureOfOperations
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:4pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p id="N1_DESCRIPTION_BUSINESS" style="margin-bottom:0pt;margin-top:4pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>DESCRIPTION OF BUSINESS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neuronetics, Inc., or the Company, is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The Company’s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system was cleared in 2008 by the United States Food and Drug Administration, or the FDA, to treat adult patients with major depressive disorder, or MDD, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar Advanced Therapy is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COVID-19</p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is monitoring the impact of the COVID-19 pandemic on all aspects of its business and geographies, including how it will impact the Company’s customers, supply chain, employees and other business partners. While the Company began to experience significant disruptions in March 2020 through the end of June 2020, from the COVID-19 pandemic, it is unable to predict the full impact that the COVID-19 pandemic may have on its financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. The outbreak of COVID-19 in many countries, including the United States, has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets.</p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applied for and received a $6.4 million loan in April 2020 under the Paycheck Protection Program (the “PPP”) established by the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) on March 27, 2020.  Due to questions concerning the eligibility of public companies similarly situated to the Company, on May 7, 2020, the Company repaid the loan in full, including interest accrued to date.</p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, the Company had cash and cash equivalents of $54.0 million and an accumulated deficit of $270.5 million. The Company incurred negative cash flows from operating activities of $30.5 million for the year ended December 31, 2019 and $23.1 million for the six months ended June 30, 2020. The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company continues to invest in sales, marketing and product development activities. The Company’s primary sources of capital to date have been proceeds from its IPO, private placements of its convertible preferred securities, borrowings under its credit facilities and revenues from sales of its products. As of June 30, 2020, the Company had $35.0 million of borrowings outstanding under its credit facility, which has a final maturity in February 2025. As discussed in Note 12, the outstanding balance under the credit facility is classified as a current liability as of June 30, 2020. Management believes that the Company’s cash and cash equivalents and anticipated revenues from sales of its products are sufficient to fund the Company’s operations (including the potential repayment of the credit facility if a waiver or amendment is not obtained) for at least 12 months from the issuance of these financial statements.   </p>
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54000000.0
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-270500000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30500000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23100000
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>BASIS OF PRESENTATION </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, promulgated by the Financial Accounting Standards Board, or FASB. </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interim Financial Statements </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission, or SEC, which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets and statements of operations and stockholders’ deficit and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of operations and cash flows for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company’s Form 10-K filed with the SEC on March 3, 2020, wherein a more complete discussion of significant accounting policies and certain other information can be found. </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.</p>
CY2020Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
7990000
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
7117000
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1354000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
548000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6636000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6569000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3107000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3314000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2279000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2207000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
828000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1107000
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
us-gaap Lessee Finance Lease Lease Not Yet Commenced Description
LesseeFinanceLeaseLeaseNotYetCommencedDescription
The Company does not currently have any finance leases or executed leases that have not yet commenced.
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2019Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y7M6D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2020Q1 stim Reimbursement Of Leasehold Expenses
ReimbursementOfLeaseholdExpenses
800000
us-gaap Operating Lease Payments
OperatingLeasePayments
394000
us-gaap Operating Lease Payments
OperatingLeasePayments
175000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4164000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
297000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
616000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
641000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
637000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
646000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
2147000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4984000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1136000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3848000
CY2020Q2 us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
474000
CY2019Q2 us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
118000
us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
726000
us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
262000
CY2020Q2 us-gaap Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
474000
CY2019Q2 us-gaap Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
118000
us-gaap Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
726000
us-gaap Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
262000
CY2020Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Remainder Of Fiscal Year
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear
653000
CY2020Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
1347000
CY2020Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
1143000
CY2020Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Four Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears
244000
CY2020Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
3387000
CY2020Q2 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
3400000
CY2020Q2 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
0
CY2020Q2 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
100000
CY2019Q2 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
100000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
200000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
300000
CY2020Q2 stim Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
368000
CY2019Q4 stim Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
674000
CY2020Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
113000
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
127000
CY2020Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
559000
CY2019Q2 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
40000.00
us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
400000
us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
100000
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
639000
CY2020Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
432000
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
280000
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
150000
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
430000
stim Amortization Period Of Deferred Sales Commissions
AmortizationPeriodOfDeferredSalesCommissions
P7Y
CY2020Q2 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
200000
CY2020Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3288000
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5724000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
557000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
373000
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
700000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
234000
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
344000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
560000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5661000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9031000
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.42
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.17
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.12
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.13
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.13
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.03
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1
CY2020Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
400000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1300000
stim Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
1
CY2020Q2 stim Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
1
CY2019Q2 stim Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
0
stim Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
0
CY2020Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35000000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2020Q2 stim Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
1925000
CY2019Q4 stim Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
1838000
CY2020Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2552000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
690000
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
34373000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
31148000
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
34373000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
11250000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19898000
CY2020Q2 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
1000000.0
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
800000
CY2020Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
200000
CY2019Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
700000
CY2019Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
200000
us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
2500000
us-gaap Interest Expense Debt
InterestExpenseDebt
2200000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
300000
us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
1900000
us-gaap Interest Expense Debt
InterestExpenseDebt
1500000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
400000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18809000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18645000
CY2020Q2 stim Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
23971000
CY2019Q4 stim Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
23046000
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
646000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1022000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1842000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1523000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
stim Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Weighted Average Grant Date Fair Value Of Underlying Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageGrantDateFairValueOfUnderlyingCommonStock
2.94
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.94
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1

Files In Submission

Name View Source Status
0001564590-20-036161-index-headers.html Edgar Link pending
0001564590-20-036161-index.html Edgar Link pending
0001564590-20-036161.txt Edgar Link pending
0001564590-20-036161-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stim-10q_20200630.htm Edgar Link pending
stim-10q_20200630_htm.xml Edgar Link completed
stim-20200630.xsd Edgar Link pending
stim-20200630_cal.xml Edgar Link unprocessable
stim-20200630_def.xml Edgar Link unprocessable
stim-20200630_lab.xml Edgar Link unprocessable
stim-20200630_pre.xml Edgar Link unprocessable
stim-ex102_219.htm Edgar Link pending
stim-ex103_80.htm Edgar Link pending
stim-ex104_218.htm Edgar Link pending
stim-ex105_217.htm Edgar Link pending
stim-ex106_216.htm Edgar Link pending
stim-ex107_215.htm Edgar Link pending
stim-ex108_214.htm Edgar Link pending
stim-ex311_9.htm Edgar Link pending
stim-ex312_7.htm Edgar Link pending
stim-ex321_6.htm Edgar Link pending
stim-ex322_8.htm Edgar Link pending